Belén Garijo
From Wikipedia, the free encyclopedia
Belén Garijo (born 31 July 1960) is a Spanish business executive. Since May 2021, she has been the CEO and chair of the executive board of Merck Group.[1][2]
Garijo was born on 31 July 1960 in Almansa, Spain.[3] She graduated from the University of Alcalá in 1983 with a degree in medicine.[4]
Career
Early beginnings
Garijo was a physician at Hospital Universitario La Paz.[5]
In 2003, Garijo became managing director of Aventis Spain, leading the merger with Sanofi. Over the course of 15 years at Sanofi, she was vice president of pharmaceutical operations for Europe and Canada and a member of the executive committee.[6]
Merck, 2011–2026
In 2011, Garijo became chief operating officer of Merck Group, until being promoted to president in 2013 and elected a board member in 2015. In May 2021, she was named chief executive officer of Merck, following Stefan Oschmann.[7][8] At the time, she was the first woman to head a company listed in Germany's stock market index DAX; she also became one of the top earners among the executives of DAX companies.[9]
As Merck CEO, Garijo oversaw strategic acquisitions such as biopharmaceutical company SpringWorks Therapeutics and portfolio divestitures.[10] Also in her capacity as CEO, she accompanied Chancellor Olaf Scholz on state visits to China in 2022[11] and 2024.[12]
Sanofi 2026–
On February 11, 2026, it was announced Garijo will become CEO of Sanofi in late April 2026.[13]
